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Abstract To investigate the signal transduction events under-
lying amylin’s actions, the amylin-evoked protein phosphoryla-
tion cascade was analysed using two-dimensional gel
electrophoresis. We found that phosphorylation of three iso-
electric variants of P20 (termed ARPP1, ARPP2 and ARPP3)
was associated with amylin’s actions in rat skeletal muscle.
Amylin decreased phosphorylation of ARPP1 and increased
phosphorylation of ARPP2 and ARPP3 in a dose-dependent
manner. Insulin inhibited amylin-evoked phosphorylation of
ARPP2 and ARPP3. The amylin-selective antagonist rat
amylin-(8^37) completely reversed amylin’s action on ARPP3
and partially decreased phosphorylation of ARPP2. By contrast,
the CGRP-selective antagonist, human CGRP-(8^37) blocked
phosphorylation of ARPP2 but had little effect on ARPP3.
These results suggest that amylin modifies phosphorylation of
P20 via two independent mechanisms, and that P20 might be a
molecule mediating amylin’s biological functions.
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1. Introduction
Amylin, a 37-amino acid polypeptide, is the major protein
component of the islet amyloid typically found in the pancre-
atic islets of non-insulin-dependent diabetes mellitus patients
[1]. Amylin is cosecreted from the pancreatic islet L-cells along
with insulin [2]. Many studies have demonstrated that amylin
is involved in controlling glucose homeostasis [3]. In skeletal
muscle, amylin promotes net loss of glycogen and increases
lactate output, probably by inactivating glycogen synthase,
inhibiting glucose uptake and activating glycogen phospho-
rylase [4^6]. It has also been reported to antagonise insulin’s
metabolic functions in vitro and in vivo [7,8]. Although earlier
results suggested that amylin’s biological e¡ects on fuel me-
tabolism were only of pharmacological interest [3], more re-
cent in vivo studies with an amylin-selective antagonist have
shown that they are likely to be of physiological relevance [8].
More recently, amylin has been proposed as a brain-gut pep-
tide participating in the rapid endocrine response during di-
gestion to maintain euglycaemia [9]. It can inhibit acid gastric
secretion, gastric emptying and food uptake [10]. Possible
roles for amylin in causing insulin resistance have been sug-
gested. Agonists and antagonists of amylin are currently
under development for clinical trials in diabetic patients
[11].
Despite considerable investigation, little is known about the
receptor and post-receptor events linking amylin to its ¢nal
biological activities. Amylin has about 50% sequence identity
with calcitonin gene-related peptide (CGRP) [3]. Some of
amylin’s e¡ects such as vasodilation and inhibition of muscle
contraction appear to be mediated by a CGRP receptor [12^
14]. On the other hand, there is evidence arguing for the ex-
istence of an amylin-speci¢c receptor [15]. Studies are also
con£icting as to whether or not amylin elicits its functions
through a cAMP-mediated pathway [5,16].
We show here that amylin-evoked signalling cascades con-
verge on P20 in rat hindlimb skeletal muscle. P20 is a small
heat shock-related protein whose function has recently been
linked to muscle contractile activity [17]. Amylin, by acting
through at least two independent mechanisms, modulates
phosphorylation of P20 to produce three phosphorylated iso-
forms. This e¡ect can be di¡erentially blocked by amylin an-
tagonists rat amylin-(8^37), human CGRP-(8^37) and insulin.
2. Materials and methods
2.1. Muscle dissection and metabolic labelling
Dissection and isolation of rat extensor digitorum longus (EDL)
muscle strips from 18-h fasted male Wistar rats (V250 g) were carried
out under anaesthesia with pentobarbital. The muscle strips were pre-
incubated in a shaking incubator at 30‡C for 1 h in 5 ml of Dulbecco’s
modi¢ed Eagle’s medium without sodium phosphate. Subsequently
the muscle strips were transferred to similar £asks containing identical
medium plus 0.25 mCi/ml [32P]orthophosphate (ICN) and incubated
for a further 4 h at 30‡C to equilibrate the internal ATP pool. All
incubation media were gassed with a mixture of 95% O2 and 5% CO2.
Rat amylin, rat amylin-(8^37), human CGRP-(8^37) (Bachem, Tor-
rance, CA) or human insulin (Actrapid, NovoNordisk) were added to
the incubation medium to stated ¢nal concentrations. Reactions were
terminated by freezing muscle strips in liquid nitrogen immediately
after incubation.
2.2. Preparation of muscle extracts and two-dimensional gel
electrophoresis (2-DE)
32P-labelled muscle strips were homogenised in 2-DE lysis bu¡er
(9 M urea, 4% w/v CHAPS, 2% v/v Pharmalyte pH 3^10, 200 mM
DTT, 8 mM PMSF). The lysates were brie£y sonicated, incubated on
ice for 20 min and microcentrifuged at 12 000 rpm for 10 min to
remove debris. Protein concentrations were determined by the Brad-
ford method and radioactivity was measured by liquid scintillation
counting. 32P-labelled lysates with equivalent amounts of radioactivity
were isoelectrically focused on IPG Drystrip pH 4^7 Linear gels
(Pharmacia) using a multiphor RII electrophoresis system according
to the manufacturer’s instructions. Second-dimensional electrophore-
sis was carried out on the ExcelGel precast 12^14% acrylamide gra-
dient gels (Pharmacia). After electrophoresis the gels were ¢xed and
the proteins visualised by Coomassie brilliant blue R250 staining,
autoradiography or phosphorimaging. In all ¢gures, the gels are dis-
played with the acid end of the isoelectric focusing dimension to the
right and the direction of SDS-PAGE from top to bottom.
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2.3. In-gel trypsin digestion, RP-HPLC and amino acid sequencing
Protein spots of interest were excised and pooled from Coomassie
brilliant blue-stained preparative gels. Gel pieces were subjected to in-
gel trypsin digestion as described by Rosenfeld et al. [18]. The ex-
tracted peptide mixture was fractionated by reverse phase HPLC
(RP-HPLC) on a Jupiter 5 W C18 column (Phenomenex) and collected
manually. Amino acid sequencing was performed using the Edman
degradation method with a Perkin Elmer (Procise, Model 492) protein
sequencer.
2.4. Immunoprecipitation
32P-labelled EDL muscle strips were solubilised by homogenising in
lysis bu¡er (1% Triton X-100, 50 mM HEPES pH 7.5, 100 mM NaCl,
10% glycerol, 5 mM EDTA, 2 mM PMSF, 10 U/ml apyrase) and
incubated on ice for 30 min with shaking. The debris was removed
by microcentrifugation and immune complexes formed by shaking the
clari¢ed muscle lysate with antisera against P20 (provided by Dr.
Kanefusa Kato) [19] overnight at 4‡C, then recovered following addi-
tion of protein A Sepharose for 1 h. 32P-labelled immunoprecipitated
proteins were eluted from the beads by incubating with 2-DE lysis
bu¡er at 60‡C for 30 min and separated by 2-DE as above.
2.5. Data analysis
Autoradiography ¢lms were scanned and digitised using a Sharp
JX-325 scanner, and protein spots detected, quantitated and analysed
using Imagemaster 2D software (Pharmacia). Radioactivity of protein
spots was also simultaneously quantitated by phosphorimager (BAS
2000). All the results presented are based on at least three independent
experiments.
3. Results
3.1. Rat amylin alters the pattern of protein phosphorylation in
rat hindlimb skeletal muscle
To detect phosphoproteins that are responsive to amylin’s
action, EDL muscle strips were prelabelled with 32P for 4 h
and subsequently treated with or without 100 nM amylin for
1 h. Alterations of phosphorylation/dephosphorylation in sev-
eral groups of proteins were consistently observed (all these
proteins are here termed ARPP (amylin-responsive phospho-
protein) for convenience) (Fig. 1). Phosphorylation of ARPP1
(pI 6.0, MW 20 kDa) was decreased 2.1-fold. Phosphorylation
of four proteins was signi¢cantly increased after stimulation,
by on average 3^8-fold individually (ARPP2 (pI 5.9, MW
20 kDa), ARPP4 (pI 5.7, MW 14 kDa), ARPP5 (pI 4.8,
MW 17 kDa) and ARPP7 (pI 5.4, MW 28 kDa)). 32P labelling
signals of two proteins (ARPP3 (pI 5.6, MW 20 kDa) and
ARPP6 (pI 5.7, MW 28 kDa)), which were only just detect-
able in control muscle strips, became very prominent in amy-
lin-treated samples.
3.2. ARPP1, ARPP2 and ARPP3 are di¡erent phosphorylated
isoforms of P20
Alterations in phosphorylation of ARPP1, ARPP2 and
ARPP3 occurred as early as 3 min after commencement of
amylin stimulation (data not shown), suggesting that they
might be early components in amylin-evoked signal transduc-
tion. In addition, the three proteins are abundant enough to
be visible on silver-stained gels (data not shown). Thus we
decided to further investigate these three ARPPs. Both
ARPP1 and ARPP2 were identi¢ed as P20 by amino acid
sequencing of the RP-HPLC-separated tryptic peptides from
these two proteins. P20 is a small heat shock-related protein
that has been reported to exist as three phosphorylated iso-
forms with similar molecular weights and di¡erent pI in
smooth muscle [17]. Immunoprecipitation of 32P-labelled
muscle lysates using antibody against P20 further con¢rmed
that ARPP1, ARPP2 and ARPP3 are three phosphorylated
isoforms of P20 in rat skeletal muscle. The pattern of in-
creased phosphorylation of ARPP2, ARPP3 and decreased
phosphorylation of ARPP1 mirrors that detected in the above
phosphoprotein maps (Fig. 2). The identities of these three
Fig. 1. Changes of protein phosphorylation in rat EDL muscle after
amylin stimulation. 32P-prelabelled (4 h) EDL muscle strips were
treated without or with 100 nM rat amylin for 1 h. Samples with
equivalent amounts of radioactivity were separated by 2-DE and
visualised by autoradiography. The arrows and numbers indicate
the spots a¡ected by amylin as described in the text.
Fig. 2. Multiple phosphorylated isoforms of P20 exist in rat EDL.
32P-prelabelled muscle extracts treated with or without amylin were
immunoprecipitated using anti-P20 antibody. The muscle lysates
(A,B) or the immunoprecipitated complexes (C,D) were separated
by 2-DE and visualised by autoradiography. The three phosphoryl-
ated isoelectric variants of p20 are numbered 1, 2 and 3.
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proteins were also veri¢ed by Western blotting (data not
shown).
3.3. Amylin-evoked phosphorylation of P20 is concentration-
dependent
The responsiveness of three isoforms of P20 to amylin’s
action di¡ers with varying amylin concentrations (Fig. 3).
Phosphorylation of ARPP3 is signi¢cantly increased by 1 nM
amylin, reaching a maximum by 10 nM. Conversely, there is
only a slight increase in phosphorylation of ARPP2 and a
decrease in phosphorylation of ARPP1 at 1 nM amylin;
maximum e¡ects on these two isoforms were only achieved
at 100 nM amylin.
3.4. E¡ects of amylin antagonists on amylin-evoked
phosphorylation of P20
Rat amylin-(8^37) and human CGRP-(8^37) have been
shown to partially or completely block amylin’s functions
[8,12,15]. Therefore, their actions on the amylin-associated
phosphorylation of P20 were also evaluated in this study.
When EDL muscle strips were co-stimulated by rat amylin
and rat amylin-(8^37) at a molar ratio of 1:500, amylin-stimu-
lated phosphorylation of ARPP3 was completely blocked
(Fig. 4C), whereas the phosphorylation of ARPP2 decreased
by only about 20% compared with that from samples stimu-
lated by amylin alone (Fig. 4B). By increasing the molar ratio
to 1:5000, phosphorylation of ARPP2 was further decreased
(by 81%), but was still not totally suppressed (Fig. 4D). By
contrast, a 500-fold molar excess of CGRP-(8^37) over amylin
slightly inhibited phosphorylation of ARPP2 but had no e¡ect
on ARPP3 (Fig. 4E). A 5000:1 ratio of CGRP-(8^37) over
amylin blocked phosphorylation of ARPP2 by 86% compared
to that in samples treated with an equivalent concentration of
amylin alone, whereas phosphorylation of ARPP3 was still
little a¡ected (Fig. 4F). Insulin inhibited amylin-evoked phos-
phorylation of ARPP2 and ARPP3 by 72% and 76% respec-
tively (Fig. 4G).
4. Discussion
P20 is a small heat shock-related protein that was recently
isolated from rat and human skeletal muscle as a by-product
of the puri¢cation of HSP28/27 [19]. While it is ubiquitously
distributed, the expression level is much higher in skeletal,
smooth and heart muscle [20]. Rat P20 is composed of 162
amino acid residues and has signi¢cant sequence similarities
with KB crystallin (47%) and HSP27 (35%). However, unlike
these two proteins, P20 is not inducible by heat shock stress in
rat skeletal muscle [19]. The physiological function of P20 is
still uncertain.
In the current study, we found that amylin modulated phos-
phorylation of P20 to produce three isoelectric isoforms
(ARPP1 with pI 6.0; ARPP2 with pI 5.9 and ARPP3 with
pI 5.6) in rat skeletal muscle. Our data support the notion
that amylin stimulates phosphorylation of ARPP2 and
ARPP3 through two independent mechanisms. (I) The re-
sponsiveness of these two isoforms to di¡erent amylin concen-
trations is distinct. Phosphorylation of ARPP3 is signi¢cantly
increased by 1 nM and saturated by 10 nM amylin, whereas
ARPP2 is maximally stimulated only by 100 nM amylin (Fig.
3). (II) The amylin-selective antagonist rat amylin-(8^37) has
separate e⁄cacy on blocking amylin’s action on these two
isoforms (Fig. 4). A 500-fold molar excess of rat amylin-(8^
37) over amylin completely reversed amylin-evoked phospho-
rylation of ARPP3, whereas a 5000-fold ratio still could not
completely block amylin’s action on ARPP2.
It remains to be determined whether amylin acts through a
speci¢c receptor, or only a CGRP receptor. Previous studies,
which were based on either binding activity [21^23] or sensi-
tivity to antagonists’ blocking e¡ects on similar post-receptor
e¡ects [15,24], could not provide an unequivocal answer. Our
Fig. 3. Distinctive phosphorylation patterns of P20 in response to
varying amylin concentrations. 32P-prelabelled rat EDL muscle
strips were treated for 1 h without amylin (A), or with 1 nM (B),
10 nM (C), or 100 nM amylin (D), then analysed as described. The
graph in the right panel represents fold increases or decreases in ra-
dioactivity of each phosphorylated form of P20 in relation to that
in the untreated muscle strips.
Fig. 4. Amylin antagonists in£uence amylin-stimulated phosphoryla-
tion of P20. 32P-prelabelled rat EDL muscle strips were incubated
for 1 h without (A) or with (B) 10 nM rat amylin, 10 nM rat amy-
lin plus 5 WM rat amylin-(8^37) (C), 10 nM rat amylin plus 50 WM
rat amylin-(8^37) (D), 10 nM rat amylin plus 5 WM human CGRP-
(8^37) (E), 10 nM amylin plus 50 WM human CGRP-(8^37) (F) or
10 nM amylin plus 71 nM insulin and analysed by 2-DE (G).
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study showed that amylin antagonists have separate e¡ects on
amylin-evoked phosphorylation of di¡erent P20 isoforms
(Fig. 4). We thus infer that both an amylin-speci¢c receptor
and a CGRP receptor are likely to be involved in amylin-
evoked phosphorylation of P20 in skeletal muscle. Low con-
centrations of amylin (6 10 nM) evoke phosphorylation of
ARPP3, perhaps via its speci¢c receptor with high a⁄nity
and low abundance, which can be completely blocked by
the speci¢c antagonist amylin-(8^37). In contrast, amylin-
stimulated phosphorylation of ARPP2 is likely to be mediated
by non-speci¢c binding of amylin to a Gs-coupled CGRP
receptor with higher capacity and lower a⁄nity, through the
cAMP pathway [25], which requires higher concentrations of
amylin and is more sensitive to antagonism by CGRP-(8^37).
Several recent studies have linked the function of P20 with
muscle contractile activity [20,26,27]. Phosphorylation of P20
has been linked to vasodilation [17] and contraction of
smooth muscle [28]. P20 might regulate vasorelaxation
through a direct interaction with contractile regulatory pro-
teins such as actin and myosin [29]. Coincidentally, many of
amylin’s biological functions are associated with muscle con-
tractile activity. For example, amylin has been shown to in-
duce vasorelaxation [12,13], inhibit electrically stimulated
muscle contraction [14,30,31] and decrease gastric motility
[9]. Moreover, the contractile status of muscle is also an im-
portant factor in regulating fuel metabolism [32,33]. There-
fore, P20 could be a critical signalling molecule which medi-
ates amylin’s physiological functions. It is interesting to note
that insulin inhibits amylin’s action on phosphorylation of
P20. Thus, P20 could serve as a marker to dissect the mech-
anisms of the interplay between amylin and insulin.
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